Stockscreener 앱 받기
20.02
1.68%
0.33
시간 외 거래:
20.30
0.28
+1.40%
전일 마감가:
$19.69
열려 있는:
$19.9
하루 거래량:
401.17K
Relative Volume:
1.16
시가총액:
$1.45B
수익:
$384.10M
순이익/손실:
$-9.07M
주가수익비율:
-143.00
EPS:
-0.14
순현금흐름:
$11.10M
1주 성능:
+1.42%
1개월 성능:
+7.00%
6개월 성능:
-24.25%
1년 성능:
+0.30%
1일 변동 폭
$19.50
$20.09
1주일 범위
$19.31
$20.20
52주 변동 폭
$16.56
$28.15
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
20.02 | 1.45B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2024-05-03 | 개시 | Wells Fargo | Overweight |
| 2020-06-29 | 재확인 | BofA Securities | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-12-12 | 재확인 | Wedbush | Outperform |
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire Inc.
Kiniksa Pharmaceuticals COO Tessari Eben sells $273,980 in shares - MSN
Kiniksa Pharmaceuticals COO sells shares worth $273,980 - MSN
Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain - Seeking Alpha
Kiniksa Pharmaceuticals COO sells shares worth $273,980 By Investing.com - Investing.com Canada
Kiniksa Pharmaceuticals International Plc (KNSA) Stock: Tracking the Weekly Performance - The News Heater
Is Kiniksa Pharmaceuticals International Plc (KNSA) a opportunity to investors? - US Post News
Keeping an Eye on Kiniksa Pharmaceuticals International Plc (KNSA) After Insider Trading Activity - Knox Daily
Stock Market Recap: Kiniksa Pharmaceuticals International Plc (KNSA) Concludes at 18.88, a -3.67 Surge/Decline - The Dwinnex
Exploring High Growth Tech Stocks in the United States - Simply Wall St
Kiniksa Pharmaceuticals Reports Strong 2024 Financial Results and Provides 2025 Revenue Guidance - Defense World
Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $255,413 - Investing.com India
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance - The Manila Times
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net - GlobeNewswire
Kiniksa's ARCALYST Soars 79% to $416M in 2024, Projects Strong 2025 Growth to $580M - StockTitan
Kiniksa Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $470k - Investing.com
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Acquired by Fmr LLC - Defense World
Kiniksa Pharmaceuticals CFO sells shares worth $593,997 By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals CFO sells shares worth $593,997 - Investing.com
Kiniksa Pharmaceuticals CFO sells shares worth $323,008 By Investing.com - Investing.com Canada
Kiniksa Pharmaceuticals CFO sells shares worth $323,008 - Investing.com India
KNSA (Kiniksa Pharmaceuticals International) Treasury Stock : $0.0 Mil (As of Sep. 2024) - GuruFocus.com
Kiniksa Pharmaceuticals officer sells $194k in stock By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals officer sells $194k in stock - Investing.com India
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference - Marketscreener.com
Principal Financial Group Inc. Sells 14,100 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals COO sells shares valued at $357,680 By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals COO sells shares valued at $357,680 - Investing.com India
HHLR Advisors, Ltd. Reduces Stake in Kiniksa Pharmaceuticals Int - GuruFocus.com
Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025? - Insider Monkey
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference 2024 | KNSA Stock News - StockTitan
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference - GlobeNewswire
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kiniksa Pharmaceuticals International Plc 주식 (KNSA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tessari Eben | CHIEF OPERATING OFFICER |
Feb 10 '25 |
Sale |
19.57 |
14,000 |
273,980 |
81,975 |
3.23%
3.94%
자본화:
|
볼륨(24시간):